



# Q1 2026 Results

Conference call and webcast for investors  
and analysts

29 April 2026



# Cautionary statements regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the risk of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements or stakeholder expectations with respect to the environment; the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery anti-corruption, anti-fraud and scientific exchanges; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; and the risk of unexpected deterioration in the Group's financial position.



# Q1 2026 Results

## Conference call agenda

<b>CEO Opening Remarks</b>	<b>Pascal Soriot</b> Chief Executive Officer	
<b>Financial Results</b>	<b>Aradhana Sarin</b> Chief Financial Officer	
<b>Oncology Haematology</b>	<b>Dave Fredrickson</b> EVP, Oncology Haematology Business	<b>Susan Galbraith</b> EVP, Oncology Haematology R&D
<b>BioPharmaceuticals</b>	<b>Ruud Dobber</b> EVP, BioPharmaceuticals Business	<b>Sharon Barr</b> EVP, BioPharmaceuticals R&D
<b>Rare Disease</b>	<b>Marc Dunoyer</b> Chief Executive Officer, Alexion	
<b>CEO Closing Remarks, Q&amp;A</b>	<b>Pascal Soriot</b> Chief Executive Officer	





# CEO Opening Remarks

**Pascal Soriot**  
CHIEF EXECUTIVE OFFICER



# Strong commercial performance in Q1 2026 with continued excellent pipeline delivery

Sustained commercial momentum

**+8%**

Total Revenue

**+12%**

Core Operating Profit

**+5%**

Core EPS<sup>1</sup>

High-value readouts across 4 Phase III programmes<sup>2</sup>

First Phase III data for NMEs

**tozorakimab**  
COPD

**efzimefotase alfa**  
HPP

Indication expansion opportunities

**Imfinzi + Imjudo**  
locoregional HCC


**Ultomiris**  
IgAN

Executing across the business to drive growth in 2026 and beyond




# Growth driven by diverse global presence and sources of business

Q1 2026 | % Product Revenue by therapy area




Q1 2026 | % Product Revenue by geography




## Strength across therapy areas

Q1 2026 | +8% Product Revenue (\$m)<sup>1</sup>



## Growth across geographies


Q1 2026 | +8% Product Revenue (\$m)<sup>1</sup>



# Continuing our successful pipeline delivery across TAs

Key Phase III trial readouts in Q1 2026

*Imfinzi + Imjudo*



Locoregional HCC

tozorakimab



COPD

efzimfotase alfa



HPP


*Ultomiris*



IgAN

Multiple high-value readouts reinforcing progress towards 2030 Ambition





# Financial Results

**Aradhana Sarin**

CHIEF FINANCIAL OFFICER



# Q1 2026 – Reported profit and loss

	Q1 2026 \$m	CER change %	% Total Revenue
- Product Sales	14,386	7	94
- Alliance Revenue	825	26	5
<b>Product Revenue</b>	<b>15,211</b>	<b>8</b>	<b>99</b>
- Collaboration Revenue	77	-	1
<b>Total Revenue</b>	<b>15,288</b>	<b>8</b>	<b>100</b>
<i>Gross Margin</i>	82%	+1pp	
- R&D expense	(3,492)	7	23
- SG&A expense	(4,920)	6	32
Total operating expense <sup>1</sup>	(8,553)	6	56
Other operating income and expense	189	65	1
Operating profit	4,246	17	28
Tax rate	21%		
<b>Reported EPS</b>	<b>\$1.99</b>	<b>8</b>	

<sup>9</sup> Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER compared to Q1 2025.

1. Total operating expense includes distribution, R&D and SG&A expenses.

Appendix: [Glossary](#).



# Q1 2026 – Core profit and loss

	Q1 2026 \$m	CER change %	% Total Revenue
- Product Sales	14,386	7	94
- Alliance Revenue	825	26	5
<b>Product Revenue</b>	<b>15,211</b>	<b>8</b>	<b>99</b>
- Collaboration Revenue	77	-	1
<b>Total Revenue</b>	<b>15,288</b>	<b>8</b>	<b>100</b>
<i>Gross Margin</i>	83%	+1pp	
- R&D expense	(3,461)	8	23
- SG&A expense	(3,859)	7	25
Total operating expense <sup>1</sup>	(7,461)	7	49
Other operating income and expense	189	63	1
Operating profit	5,352	12	35
Tax rate	21%		
<b>Core EPS<sup>2</sup></b>	<b>\$2.58</b>	<b>5</b>	

<sup>10</sup> Due to rounding, the sum of the dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER compared to Q1 2025.

1. Total operating expense includes distribution, R&D and SG&A expenses. 2. EPS growth reflects the favourable tax rate in the prior year period.


Appendix: [Glossary](#).



# FY 2026 guidance reiterated

Capital allocation priorities remain unchanged

## Net debt/EBITDA 1.3x




## FY 2026 Guidance (CER)

<b>Total Revenue</b>	Anticipated to <b>increase by a mid-to-high single-digit</b> percentage
<b>Core EPS</b>	Anticipated to <b>increase by a low double-digit</b> percentage

- Core tax rate expected to be between 18-22%
- Anticipated FX impact<sup>5</sup>: low single-digit positive impact on Total Revenue and neutral on Core EPS

Due to rounding, the sum of the dollar values and percentages may not agree to totals. 1. Capital expenditure on tangible assets and software-related intangible assets. 2. Comprises purchase and disposal of intangible assets (excluding software-related assets, including AZ Forest), movement in profit participation liability, purchase and disposal of non-current asset investments, payments to associates and joint ventures, payments to acquire non-controlling interests, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt and payment of contingent consideration on business combinations. The Company mainly uses debt issuance or available cash to finance new Business Development opportunities. 3. Comprises mainly shares purchased by Employee Benefit Trust. 4. Rolling 12-month EBITDA. AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A1, outlook positive. S&P Global Ratings: short-term rating A-1, long-term rating A+, outlook stable. 5. If foreign exchange rates for April 2026 to December 2026 were to remain at the average rates seen in March 2026. Appendix: [Glossary](#).





# Oncology

**Dave Fredrickson**

ONCOLOGY HAEMATOLOGY BUSINESS


**Susan Galbraith**

ONCOLOGY HAEMATOLOGY R&D



# Oncology – Q1 2026

Total Revenue \$6.8bn driven by strong global demand across key medicines



Tagrisso Imfinzi + Imjudo Calquence Enhertu Truqap Lynparza (PR) Others<sup>1</sup> Lynparza (CR)

## Q1 2026: key dynamics

- **Tagrisso** +5%, robust demand across indications, continued 1L combination growth
- **Imfinzi** +30%, **Imjudo** (7%), strong demand across regions, driven by new launches
- **Calquence** +17%, sustained BTKi leadership in 1L CLL in major markets
- **Enhertu** +34%, continued global demand across breast, uptake in pan-tumour
- **Truqap** +47%, further ex-US growth, 2L US share stable
- **Datroway** \$43m, ongoing demand in EGFRm lung, leading position in 3L+

### Key regulatory approvals:

- US (*Calquence* AMPLIFY), EU (*Imfinzi* MATTERHORN), JP (*Enhertu* DESTINY-Gastric04, DESTINY-PanTumor02), CN (*Enhertu* DESTINY-Breast11, *Imfinzi* DUO-E, *Imfinzi* + *Imjudo* POSEIDON, HIMALAYA)



# Oncology – advancing pipeline at ASCO 2026

Positive Phase III for *Imfinzi* + *Imjudo* in HCC, encouraging early data across portfolio

## *Imfinzi* + *Imjudo* | Moving earlier into locoregional HCC with EMERALD-3

**STRIDE  
+ lenvatinib  
+ TACE**

- ▶ Statistically significant, clinically meaningful PFS improvement vs TACE alone
- ▶ Trend to OS improvement

**STRIDE  
+ TACE**

- ▶ Strong trends to PFS and OS improvement vs TACE alone

**207k** patients with embolisation-treated locoregional HCC<sup>1</sup>

**1st of 4** high-value *Imfinzi* trials to read out in 2026<sup>2</sup>

## Further evidence for key transformative technologies at ASCO

### Expanding leadership position in growing ADC market

**puxi-sam** | BLUESTAR PhI/IIa | B7-H4 endometrial, ovarian cancers

**sone-ve** | CLARITY-PanTumor01 PhII | Cldn18.2 gastric/GEJC

### Leading in next-wave IO bispecifics


**rilvegostomig + Enhertu** | DESTINY-Gastric03 PhIb/II | HER2+ gastric/ GEJC

**volrustomig** | eVOLVE-02 PhII | HNSCC

### Advancing haematology pipeline at pace

**AZD3470 (PRMT5i)** | PRIMAVERA PhI | classical Hodgkin Lymphoma





# BioPharmaceuticals

**Ruud Dobber**

BIOPHARMACEUTICALS BUSINESS



**Sharon Barr**

BIOPHARMACEUTICALS R&D



# BioPharmaceuticals – Q1 2026

Total Revenue \$5.8bn, CVRM LoEs largely offset by growth in R&I and new products



## Q1 2026: key dynamics

- **Fasenra** +11%, sustained IL-5 leadership in asthma, EGPA launch
- **Breztri** +13%, fastest growing medicine in expanding FDC triple class in COPD
- **Tezspire** +34%, sustained demand growth in severe asthma, supported by nasal polyps launch
- **Saphnelo** +24%, increasing penetration in i.v. segment of SLE
- **Farxiga** (3%), growth in US and EM ex-CN; VBP implemented in Q1, generic competition in Japan
- **Brilinta** (67%), generic competition
- **Wainua** +28%, demand growth in ATTR-PN

## Key regulatory approvals:

- US (*Breztri* KALOS/LOGOS, *Saphnelo* TULIP-SC), JP (*Tezspire* WAYPOINT, *Saphnelo* TULIP-SC), CN (*Tezspire* DIRECTION, WAYPOINT)



# BioPharmaceuticals – expanding leadership in COPD

Tozorakimab first biologic effective in all-comers COPD population in 3 pivotal trials

## tozorakimab | Potential first-in-class IL-33 biologic in COPD

tozorakimab uniquely inhibits signaling of reduced and oxidised forms of IL-33 to address main drivers of COPD worsening

### OBERON/TITANIA

300mg tozorakimab q4w

- ▶ **Highly clinically meaningful** reduction in annualised rate of moderate to severe COPD exacerbations
- ▶ Studied in **broad population**: former and current smokers, all eosinophil counts

### MIRANDA

300mg tozorakimab q2w

- ▶ **Clinically meaningful** reduction in annualised rate of moderate to severe COPD exacerbations
- ▶ Studied in **broad population**: former and current smokers, all eosinophil counts

## Remaining high unmet need in COPD

**6 million** biologic-eligible patients in Top 8<sup>1</sup>

**<5%** currently on a biologic in Top 8<sup>2</sup>

## Trials included COPD population independent of EOS levels<sup>3</sup>

**35%**  
0-150


**35%**  
150-300

**30%**  
>300

OBERON/TITANIA/MIRANDA

tozorakimab has opportunity to redefine management of COPD with **\$3-5bn NRA PYR<sup>4</sup>**





# Rare Disease


**Marc Dunoyer**

CHIEF EXECUTIVE OFFICER, ALEXION



# Rare Disease – Q1 2026

Total Revenue \$2.4bn driven by continued patient demand across the portfolio



## Q1 2026: key dynamics

### C5 Franchise

- **Ultomiris** +18%, demand growth across indications, including within the competitive gMG and PNH markets
- **Soliris** (14%), continued successful conversion to *Ultomiris* and additional impact from biosimilars in US and EU, partially offset by favourable order timing in certain tender markets

### Beyond Complement

- **Strensiq** +43%, continued strong global demand from patients with HPP
- **Koselugo** +15%, continued global demand, including newly launched adult indication in EU and JP

### Key regulatory approvals:

CN (*Koselugo* NF1-PN adults)




# Rare Disease – extending our leadership

Two positive Phase III programmes in rare metabolic and renal diseases

## efzimfotase alfa | Positive results from global Phase III clinical programme in HPP patients

- ▶ Addresses broad disease symptomatology
- ▶ Improved dosing and COGS vs *Strensiq*
- ▶ Positioned for broader global adoption, removing key barriers to access

**~14K** addressable HPP patients in Top 8<sup>1</sup>



Next-generation enzyme replacement therapy built for global expansion with **\$3-5bn NRA PYR potential**

## Ultomiris | I CAN interim analysis showed improvement in UPCR in IgAN patients

- ▶ Demonstrated rapid, complete and sustained terminal complement inhibition, with **rapid proteinuria reduction**, as early as week 10
- ▶ Benefit seen across patients including those at higher risk of progression and with more inflammatory disease

**>560K** patients diagnosed with IgAN across US, EU5 and Japan

↳ **>60%** eligible for IgAN treatment based on proteinuria<sup>3</sup>

Established nephrology presence provides a strong foundation for *Ultomiris'* **blockbuster potential** in IgAN





# CEO Closing Remarks

**Pascal Soriot**  
CHIEF EXECUTIVE OFFICER



# Phase III pipeline momentum continues across 2026

## H1 2026

**EMERALD-3** | *Imfinzi + Imjudo*  
locoregional hepatocellular carcinoma



**VOLGA** | *Imfinzi ± Imjudo*  
muscle-invasive bladder cancer

**OBERON/TITANIA/MIRANDA** |  
tozorakimab COPD



**I CAN** | *Ultomiris*  
IgAN



**TMA-313** | *Ultomiris*  
HSCT-TMA (adults)

**HICKORY/CHESTNUT/MULBERRY** |  
efzimfotase alfa hypophosphatasia



## H2 2026

**AVANZAR** | *Datroway + Imfinzi*  
1L NSQ/NSQ TROP2+ NSCLC

**TROPION-Lung15** | *Datroway ± Tagrisso 2L*  
EGFRm NSCLC

**PACIFIC-9** | *Imfinzi + oleclumab/ monalizumab*  
unresect. stg. III NSCLC

**SAFFRON** | *Tagrisso + Orpathys*  
2L EGFRm NSCLC

**SERENA-4** | camizestrant  
1L HR+ HER2- adv. breast cancer

**CLARITY-Gastric01** | *sonesitatug vedotin 2L+*  
CLDN18.2+ gastric cancer

**CROSSING** | *Tezspire*  
eosinophilic esophagitis

**CARDIO-TTRansform** | *Wainua*  
ATTR-CM

**TILIA** | tozorakimab  
lower respiratory tract disease

**ARTEMIS** | *Ultomiris*  
CSA-AKI



Readouts in 2026 represent additional combined risk-adjusted >\$10bn PYR opportunity<sup>1</sup>



# Strong R&D execution underpins milestone-rich 2026

Key upcoming 2026 data presentations and regulatory decisions

## Key data presentations

<b>ASCO</b>   Multiple datasets PHIII EMERALD-3, CARES, SERENA-6 PFS2	May/Jun
<b>ADA</b>   elecglipton PHII SOLSTICE, VISTA	Jun
<b>Future presentation</b>   tozorakimab PHIII OBERON, TITANIA, MIRANDA	
<b>ECE</b>   eneboparatide PHIII CALYPSO	May
<b>Future presentation</b>   efzimfotase alfa PHIII MULBERRY, CHESTNUT, HICKORY	
<b>Future presentation</b>   <i>Ultomiris</i> PHIII I CAN	

## First regulatory decisions

<b>TROPION-Breast02</b>   <i>Datroway</i>		H1
<b>POTOMAC</b>   <i>Imfinzi</i>		H1
<b>CAPitello-281</b>   <i>Truqap</i>		H1
<b>SERENA-6</b>   camizestrant	NME	H1
<b>BaxHTN</b>   baxdrostat US PDUFA	NME	H1
<b>DESTINY-Breast05</b>   <i>Enhertu</i>		H2
<b>CARES</b>   anselamimab	NME	H2
<b>PREVAIL</b>   gefurulimab	NME	H2

## Subsequent major market approvals

<b>DESTINY-Breast11</b>   <i>Enhertu</i> US	H1
<b>MATTERHORN</b>   <i>Imfinzi</i> JP	H1
<b>AMPLIFY</b>   <i>Calquence</i> JP	H2
<b>DESTINY-Breast09</b>   <i>Enhertu</i> EU, JP, CN	H2
<b>DESTINY-PanTumor02</b>   <i>Enhertu</i> EU	H2
<b>KALOS/LOGOS</b>   <i>Breztri</i> EU, JP	H2



# Increasing confidence in Ambition 2030 and continued growth beyond



## Continued commercial momentum in 2026

Strong global demand across medicines



## Advancing towards \$80bn 2030 Total Revenue ambition<sup>1</sup>

Significant pipeline progress increases confidence



## Investment in growth beyond 2030

Strategic focus to fuel growth into next decade



# Q&A Session



**Pascal Soriot**  
CHIEF EXECUTIVE OFFICER



**Aradhana Sarin**  
CHIEF FINANCIAL OFFICER



**Marc Dunoyer**  
CHIEF EXECUTIVE  
OFFICER, ALEXION



**Susan Galbraith**  
EVP, ONCOLOGY HAEMATOLOGY R&D



**Dave Fredrickson**  
EVP, ONCOLOGY  
HAEMATOLOGY BUSINESS



**Sharon Barr**  
EVP, BIOPHARMACEUTICALS R&D



**Ruud Dobber**  
EVP, BIOPHARMACEUTICALS  
BUSINESS



**Iskra Reic**  
EVP, INTERNATIONAL





# Appendix




# AstraZeneca P&L reference table

## P&L line-item definitions

	P&L line-item definition
<b>Product Sales</b>	<ul style="list-style-type: none"> <li>Recognises sales from territories where Group has lead commercialisation</li> <li>Recognises supply of Beyfortus to Sanofi</li> </ul>
<b>Alliance Revenue</b>	<ul style="list-style-type: none"> <li>Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place<sup>1</sup></li> </ul>
<b>Product Revenue</b>	<ul style="list-style-type: none"> <li>The sum of Product Sales and Alliance Revenue</li> </ul>
<b>Collaboration Revenue</b>	<ul style="list-style-type: none"> <li>Recognises any development or sales-based milestone received on partnered medicines as well as any upfront payments associated with business development where AstraZeneca retains a significant ongoing economic interest in the product</li> </ul>
<b>Total Revenue</b>	<ul style="list-style-type: none"> <li>Sum of Product Sales, Alliance Revenue and Collaboration Revenue</li> </ul>
<b>Gross Margin</b>	<ul style="list-style-type: none"> <li>Calculated by dividing Gross Profit by Total Revenue</li> </ul>
<b>Other operating income &amp; expense</b>	<ul style="list-style-type: none"> <li>Other operating income and expense is generated from activities outside of the Group's normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest</li> </ul>
<b>Core<sup>2</sup> Operating margin</b>	<ul style="list-style-type: none"> <li>Defined as Core Operating profit as a percentage of Total Revenue</li> </ul>




# Non-risk adjusted peak-year revenue guidance



28 Represents non-risk adjusted peak year revenue, as provided during Investor Day, May 2024.  
Collaboration partners: Daiichi Sankyo (*Enhertu, Datroway*), Ionis (*Wainua*).  
Appendix: [Glossary](#).



# AstraZeneca in non-small cell lung cancer
















Key:



29 All numbers are approximate. Illustrative settings and populations, not to scale. Lung Cancer map reflects Phase III/pivotal trials. Collaboration partners: Daiichi Sankyo (Enhertu, Datroway), Hutchmed (Orpathys). Appendix: [Glossary](#).




# AstraZeneca in breast cancer

	Early			Metastatic			
	Neoadjuvant	Adjuvant		1st line	2nd line	3rd line	4th line +
Est. epi (G7, 2025)	540k			135k	100k	75k	60k
<b>HER2-positive</b> 15-20%	 <i>Enhertu</i> → THP <b>DESTINY-Breast11</b>	NST → residual disease → <i>Enhertu</i> <b>DESTINY-Breast05</b>		 <i>Enhertu</i> ± pertuzumab <b>DESTINY-Breast09</b>	 <i>Enhertu</i> <b>DESTINY-Breast03</b>	 <i>Enhertu</i> <b>DESTINY-Breast01/02</b>	
<b>HR-positive</b> 65-75%		Good outcomes with current SoC for low-risk patients	<b>RECURRENCE</b>	camizestrant + palbociclib <b>SERENA-4</b>	 <i>Truqap</i> + <i>Faslodex</i> <b>CAPitello291</b> <i>PIK3CA, AKT1, PTEN alt.40%</i>	 <i>Datroway</i> <b>TROPION-Breast01</b>	
		CTx → camizestrant ± abemaciclib <b>CAMBRIA-2</b>		AI + CDK4/6i → camizestrant + CDK4/6i <b>SERENA-6</b> <i>ESR1m 35%</i>			 <i>Enhertu</i> <b>DESTINY-Breast06</b> HER2-low (1+, 2+) 60% HER2-ultralow (0-1+) 25%
		CTx → AI ± CDK4/6i 2-5 yrs → camizestrant <b>CAMBRIA-1</b>		 <i>Truqap</i> + <i>Faslodex</i> + CDK4/6i <b>CAPitello292</b>	 saruparib + camizestrant <b>EvoPAR-Breast01</b> <i>tBRCAm, PALB2m 9%</i>		
<b>TNBC</b> 10-15%	 <i>Datroway</i> + <i>Imfinzi</i> <b>TROPION-Breast04</b>	NST → residual disease → <i>Datroway</i> ± <i>Imfinzi</i> <b>TROPION-Breast03</b>		 <i>Datroway</i> + <i>Imfinzi</i> <b>TROPION-Breast05</b> PD-L1-eligib. 30%			
				 <i>Datroway</i> <b>TROPION-Breast02</b> PD-L1-inelig. 70%			
<b>gBRCAm</b> 5% of HR-positive 15% of TNBC		CTx → <i>Lynparza</i> <b>OlympiA</b>			 <i>Lynparza</i> <b>OlympiAD</b>		

Key:  DXd ADC  IO  ngSERD  AKTi  PARPi  launched and established SoC  launched indication



# AstraZeneca in gastric cancer



Key:

DXd ADC

IO

AZ ADC

IO bispecific

launched and established SoC


launched indication



# Oncology


## Tagrisso

5% growth at CER to \$1,833m in Q1 2026



## Lynparza


2% growth at CER to \$781m in Q1 2026



# Oncology


## Imfinzi

30% growth at CER to \$1,694m in Q1 2026



## Imjudo


7% decrease at CER to \$77m in Q1 2026



# Oncology


## Calquence

17% growth at CER to \$923m in Q1 2026



## Enhertu


34% growth at CER to \$831m in Q1 2026



# BioPharmaceuticals: Respiratory & Immunology


## Fasenra

11% growth at CER to \$483m in Q1 2026




## Tezspire

34% growth at CER to \$303m in Q1 2026



## Saphnelo


24% growth at CER to \$171m in Q1 2026



# BioPharmaceuticals: Respiratory & Immunology


## Breztri

13% growth at CER to \$353m in Q1 2026



## Symbicort


1% decrease at CER to \$747m in Q1 2026



# BioPharmaceuticals: Cardiovascular, Renal & Metabolism


## Farxiga

2% decrease at CER to \$2,193m in Q1 2026




## Brilinta

67% decrease at CER to \$105m in Q1 2026



## Lokelma


26% growth at CER to \$199m in Q1 2026



# Rare Disease


## Ultomiris

18% growth at CER to \$1,270m in Q1 2026




## Strensiq

43% growth at CER to \$517m in Q1 2026



## Koselugo

15% growth at CER to \$170m in Q1 2026



# Glossary

<b>1L, 2L, 3L</b>	first-, second-, third-line
<b>ADA</b>	American Diabetes Association
<b>ADC</b>	antibody-drug conjugate
<b>adv.</b>	advanced
<b>AI</b>	aromatase inhibitor
<b>AKT1</b>	AKT serine/threonine kinase 1
<b>AKTi</b>	AKT inhibitor
<b>ASCO</b>	American Society of Clinical Oncology
<b>ASI</b>	aldosterone synthase inhibitor
<b>ATTR-CM</b>	transthyretin amyloid cardiomyopathy
<b>ATTR-PN</b>	transthyretin amyloid polyneuropathy
<b>AZ</b>	AstraZeneca
<b>BCMA</b>	b-cell maturation agent
<b>BTKi</b>	Bruton's tyrosine kinase
<b>C5</b>	complement component 5
<b>CapEx</b>	capital expenditure
<b>CAR-T</b>	chimeric antigen receptor t-cell
<b>CDK4/6i</b>	cyclin-dependent kinase 4/6 inhibitor
<b>CER</b>	constant exchange rates
<b>CFO</b>	net cash inflow from operating activities
<b>CLDN18.2</b>	Claudin-18.2
<b>CLL</b>	chronic lymphocytic leukaemia
<b>CN</b>	China
<b>COGS</b>	cost of goods sold
<b>COPD</b>	chronic obstructive pulmonary disease
<b>CR</b>	Collaboration Revenue
<b>CRT</b>	chemoradiotherapy
<b>CTLA-4</b>	cytotoxic T-lymphocyte associated protein 4
<b>CTx</b>	chemotherapy
<b>CVRM</b>	Cardiovascular, Renal and Metabolism
<b>Dxd</b>	deruxtecan
<b>EBITDA</b>	earnings before interest, tax, depreciation and amortisation
<b>ECE</b>	European Congress of Endocrinology
<b>EGFRm</b>	epidermal growth factor receptor-mutant
<b>EGPA</b>	eosinophilic granulomatosis with polyangiitis
<b>EM</b>	Emerging Markets
<b>EOS</b>	eosinophils
<b>epi</b>	epidemiology
<b>EPS</b>	earnings per share
<b>ERoW</b>	Established Rest of World
<b>ESR1m</b>	estrogen receptor alpha-mutated
<b>Eta</b>	endothelin A
<b>EU</b>	Europe
<b>FDC</b>	fixed-dose combination
<b>FLOT</b>	fluorouracil, leucovorin, oxaliplatin and docetaxel
<b>FP</b>	fluoropyrimidine
<b>FX</b>	foreign exchange
<b>FY</b>	Fiscal Year
<b>G7</b>	US, Japan, EU5
<b>gBRCAm</b>	germline BRCA-mutated breast cancer
<b>GEJC</b>	gastroesophageal junction adenocarcinoma
<b>GLP-1</b>	glucagonlike peptide-1
<b>gMG</b>	generalised myasthenia gravis
<b>HCC</b>	hepatocellular carcinoma
<b>HER2-/negative</b>	human epidermal growth factor receptor 2-negative
<b>HER2-low</b>	human epidermal growth factor receptor 2-low
<b>HER2-ultralow</b>	human epidermal growth factor receptor 2-ultralow
<b>HER2+/positive</b>	human epidermal growth factor receptor 2-positive
<b>HER2m</b>	human epidermal growth factor receptor 2-mutant
<b>HNSCC</b>	head and neck squamous cell carcinoma
<b>HPP</b>	hypophosphatasia
<b>HR+/positive</b>	hormone receptor-positive
<b>HSCT-TMA</b>	hematopoietic stem cell transplantation-associated thrombotic microangiopathy
<b>i.v.</b>	intravenous
<b>ID</b>	Infectious Disease
<b>IgAN</b>	immunoglobulin A nephropathy
<b>IL-33</b>	interleukin-33
<b>IL-5</b>	interleukin-5
<b>IO</b>	immuno-oncology
<b>JP</b>	Japan
<b>K+</b>	potassium
<b>KDIGO</b>	Kidney Disease: Improving Global Outcomes
<b>LOE</b>	loss of exclusivity
<b>M&amp;A</b>	mergers and acquisitions
<b>mAB</b>	monoclonal antibody
<b>MR</b>	mineralocorticoid receptor
<b>NF1-PN</b>	Neurofibromatosis Type 1 Plexiform Neurofibromas
<b>NME</b>	new molecular entity
<b>NMR+</b>	normalised membrane ratio positive
<b>NRA</b>	non-risk adjusted
<b>NSCLC</b>	non-small cell lung cancer
<b>NSQ</b>	non-squamous
<b>NST</b>	neoadjuvant systemic therapy
<b>OS</b>	overall survival
<b>PALB2m</b>	partner and localizer of BRCA2
<b>PARPi</b>	poly-ADP ribose polymerase inhibitor
<b>PCSK9</b>	proprotein convertase subtilisin/kexin type 9
<b>PD-1</b>	programmed cell death protein 1
<b>PD-L1</b>	programmed cell death ligand 1
<b>PDUFA</b>	Prescription Drug User Fee Act
<b>PFS</b>	progression free survival
<b>PIK3CA</b>	phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit
<b>PNH</b>	paroxysmal nocturnal haemoglobinuria
<b>pp</b>	percentage point
<b>PR</b>	Product Revenue
<b>PRMT5i</b>	protein arginine methyltransferase 5 inhibitor
<b>PS</b>	Product Sales
<b>PTEN</b>	phosphatase and TENsin homolog deleted on chromosome 10
<b>PYR</b>	Peak-Year Revenue
<b>R&amp;D</b>	Research & Development
<b>R&amp;I</b>	Respiratory & Immunology
<b>SBRT</b>	stereotactic body radiotherapy
<b>SC</b>	subcutaneous
<b>SERD</b>	selective estrogen receptor degraders
<b>SG&amp;A</b>	Selling, General & Administrative
<b>SGLT2</b>	sodium-glucose cotransporter 2
<b>SLE</b>	systemic lupus erythematosus
<b>SoC</b>	standard-of-care
<b>SQ</b>	squamous
<b>Stg.</b>	stage
<b>TACE</b>	transarterial chemoembolization
<b>tBRCAm</b>	tumor BRCA mutation
<b>TCE</b>	t-cell engager
<b>THP</b>	docetaxel, trastuzumab and pertuzumab
<b>TIGIT</b>	T-cell immunoreceptor with immunoglobulin and ITIM domains
<b>TKI</b>	tyrosine kinase inhibitor
<b>TL07</b>	TROPION-Lung07
<b>TL08</b>	TROPION-Lung08
<b>TNBC</b>	triple negative breast cancer
<b>TROP2</b>	trophoblast cell surface antigen 2
<b>UPCR</b>	urine protein to creatinine ratio
<b>US</b>	United States
<b>VBP</b>	volume-based procurement



### **Confidentiality Notice**

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful.

AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK  
+44(0)203 749 5000  
[www.astrazeneca.com](http://www.astrazeneca.com)

